Digoxin increases hydrogen sulfide concentrations in brain, heart and kidney tissues in mice

Pharmacological Reports

Volumn 63, Issue 5, 2011, Pages 1243-1247

  Wiliński, Bogdan ^a   Wiliński, Jerzy ^a   Somogyi, Eugeniusz ^a   Piotrowska, Joanna ^a   Góralska, Marta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cardiac glycosides; Digoxin; Heart; Hydrogen sulfide; Mice

Indexed keywords

DIGOXIN; DIGOXIN WZF; HYDROGEN SULFIDE; SULFUR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; HEART; KIDNEY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; SPECTROPHOTOMETRY; TISSUE LEVEL;

EID: 83155175614     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(11)70645-4     Document Type: Article

References (41)

1. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med, 1997, 336, 525-533.
2. Ahmed A, Aban IB, Weaver MT, Aronow WS, Fleg JL: Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Fail, 2006, 8, 409-419. (Pubitemid 43842120)
3. Bagrov AY, Shapiro JI, Fedorova OV: Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev, 2009, 61, 9-38.
4. Blaustein MP, Zhang J, Chen L, Hamilton BP: How does salt retention raise blood pressure? Am J Physiol Regul Integr Comp Physiol, 2006, 290, R514-523.
5. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC: The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res, 2007, 76, 29-40. (Pubitemid 47362041)
6. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ: Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemiainduced heart failure in mice. Circulation, 2010, 122, 11-19.
7. Daniel EE, El-Yazbi A, Cho WJ: Caveolae and calcium handling, a review and a hypothesis. J Cell Mol Med, 2006, 10, 529-544. (Pubitemid 44870197)
8. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X et al.: Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA, 2007, 104, 15560-15565. (Pubitemid 47502956)
9. Gadalla MM, Snyder SH: Hydrogen sulfide as a gasotransmitter. J Neurochem, 2010, 113, 14-26.
10. Gheorghiade M, Ferguson D: Digoxin. Aneurohormonal modulator in heart failure? Circulation, 1991, 84, 2181-2186.
11. Goto A, Ishiguro T, Yamada K, Ishii M, Yoshioka M, Eguchi C, Shimora M, Sugimoto T: Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun, 1990, 173, 1093-1101.
12. Hosgood SA, Nicholson ML: Hydrogen sulphide ameliorates ischaemia-reperfusion injury in an experimental model of non-heart-beating donor kidney transplantation. Br J Surg, 2010, 97, 202-209.
13. Hu Y, Chen X, Pan TT, Neo KL, Lee SW, Khin ES, Moore PK, Bian JS: Cardioprotection induced by hydrogen sulfide preconditioning involves activation of ERK and PI3K/Akt pathways. Pflugers Arch, 2008, 455, 607-616. (Pubitemid 350160475)
14. Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, Kimura H: A source of hydrogen sulfide and a mechanism of its release in the brain. Antioxid Redox Signal, 2009, 11, 205-214.
15. Kimura H: Hydrogen sulfide: its production, release and functions. Amino Acids, 2010, 136, 335-339.
16. Li L, Hsu A, Moore PK: Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation - a tale of three gases. Pharmacol Ther, 2009, 123, 386-400.
17. Lopez-Lazaro M: Digoxin, HIF-1, and cancer. Proc Natl Acad Sci USA, 2009, 106, E26.
18. 2S) - the third gas of interest for pharmacologists. Pharmacol Rep, 2007, 59, 4-24.
19. Mishra PK, Tyagi N, Sen U, Givvimani S, Tyagi SC: H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure. Am J Physiol Heart Circ Physiol, 2010, 298, H451-456.
20. Noble D: Mechanism of action of therapeutic levels of cardiac glycosides. Cardiovasc Res, 1980, 14, 495-514.
21. Norn S, Kruse PR: Cardiac glycosides: From ancient history through Withering's foxglove to endogeneous cardiac glycosides (Danish). Dan Medicinhist Arbog, 2004, 119-132.
22. Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, Kim HR, Jeon SB et al.: Hydrogen sulfide inhibits nitric oxide production and nuclear factor-κB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med, 2006, 41, 106-119. (Pubitemid 43884782)
23. Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG et al.: Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA, 2009, 106, 21972-21977.
24. Predmore BL, Lefer DJ: Development of hydrogen sulfide-based therapeutics for cardiovascular disease. J Cardiovasc Transl Res, 2010, 3, 487-498.
25. Rahimtoola SH: Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations. Eur Heart J, 2006, 27, 1630.
26. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol, 2007, 293, C509-536. (Pubitemid 47235171)
27. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, Kimura H: 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal, 2009, 11, 703-714.
28. Siegel LM: A direct microdetermination for sulfide. Anal Biochem, 1965, 11, 126-132.
29. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S et al.: Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock, 2009, 31, 267-274.
30. Somogyi E, Piotrowska J, Rzeszutko W: An effect of some parameters of the determination of the hydrogen sulfide in pig liver and brain on the obtained results (Polish). Farm Prz Nauk, 2008, 5, 33-36.
31. Srebro Z, Somogyi E, Wiliński B, Góralska M, Wiliński J, Sura P: Aspirin augments the concentration of endogenous hydrogen sulfide in mouse brain and liver. Folia Med Cracov, 2006, 47, 87-91.
32. Sun YG, Cao YX, Wang WW, Ma SF, Yao T, Zhu YC: Hydrogen sulphide is an inhibitor of L-type calcium channels and mechanical contraction in rat cardiomyocytes. Cardiovasc Res, 2008, 79, 632-641.
33. Tian J, Liu J, Garlid KD, Shapiro JI, Xie Z: Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial K(ATP) channels. Mol Cell Biochem, 2003, 242, 181-187. (Pubitemid 36240544)
34. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, Zhu YC: The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal, 2010, 12, 1065-1077.
35. Wiliński B, Wiliński J, Somogyi E, Góralska M, Piotrowska J: Paracetamol (acetaminophen) decreases hydrogen sulfide tissue concentration in brain and increases in the heart, liver and kidney in mice. Folia Biol (Kraków), 2011, 59, 41-44.
36. Wiliński B, Wiliński J, Somogyi E, Góralska M, Piotrowska J: Ramipril affects hydrogen sulfide generation in mouse liver and kidney. Folia Biol (Kraków), 2010, 58, 177-180.
37. Wiliński B, Wiliński J, Somogyi E, Piotrowska J, Góralska M: Atorvastatin affects the hydrogen sulfide tissue concentration in mouse kidneys and other organs. Pharmacol Rep, 2011, 63, 184-188.
38. Wiliński J, Somogyi E, Góralska M, Wiliński B, Czarnecka D: Ramipril enhances the endogenous hydrogen sulfide tissue concentration in mouse heart and brain. Folia Med Cracov, 2008, 49, 123-130.
39. Winnicka K, Bielawski K, Bielawska A: Synthesis and cytotoxic activity of G3 PAMAM-NH(2) dendrimermodified digoxin and proscillaridin A conjugates in breast cancer cells. Pharmacol Rep, 2010, 62, 414-423.
40. Xia M, Chen L, Muh RW, Li PL, Li N: Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J Pharmacol Exp Ther, 2009, 329, 1056-1062.
41. +-ATPase as a signal transducer. Eur J Biochem, 2002, 269, 2434-2439.